Conference Proceedings

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

Gregor Dresemann, Michael Weller, Mark A Rosenthal, Ulrich Wedding, Wolfgang Wagner, Erik Engel, Bernhard Heinrich, Regine Mayer-Steinacker, Anders Karup-Hansen, Oystein Fluge, Anna Nowak, Maximilian Mehdorn, Eberhard Schleyer, Dietmar Krex, Ian N Olver, Joachim P Steinbach, Christian Hosius, Christian Sieder, Greg Sorenson, Richard Parker Show all



A randomized, multicenter, open-label, phase 3 study of patients with progressive, recurrent glioblastoma multiforme (GBM) for whom front-line therapy had failed was conducted. This study was designed to determine whether combination therapy with imatinib and hydroxyurea (HU) has superior antitumor activity compared with HU monotherapy in the treatment of recurrent GBM. The target population consisted of patients with confirmed recurrent GBM and an Eastern Cooperative Oncology Group performance status of 0-2 who had completed previous treatment comprising surgical resection, irradiation therapy, and first-line chemotherapy (preferably temozolomide (TMZ) containing regimen) and who have progr..

View full abstract